Literature DB >> 36101561

Bullous Pemphigoid Associated with Erythrodermic Psoriasis: A Case Report.

Wenjuan Chen1,2, Chen Peng1,2, Jianfeng Zheng1,2, Xiya Lu1,2, Yangfeng Ding1,2, Lina Su1,2.   

Abstract

Psoriasis is an immune-mediated systemic disease with multiple organs involvement, such as cardiovascular, live, gut, endocrine, and so on. Bullous pemphigoid (BP) is a rare comorbidity associated with psoriasis, while BP occurring in erythrodermic psoriasis (EP) is very rare. In this case, we reported a woman with severe EP who developed BP, in whom beta hemolytic streptococcus infection was a possible triggering factor. The complicated condition of such patients needs to draw attention of the physician and study further for better treatment.
© 2022 Chen et al.

Entities:  

Keywords:  bullous pemphigoid; comorbidity; erythrodermic psoriasis

Year:  2022        PMID: 36101561      PMCID: PMC9464440          DOI: 10.2147/CCID.S374556

Source DB:  PubMed          Journal:  Clin Cosmet Investig Dermatol        ISSN: 1178-7015


  12 in total

1.  Development of bullous pemphigoid during treatment of psoriasis with adalimumab.

Authors:  B Stausbøl-Grøn; M Deleuran; E Sommer Hansen; K Kragballe
Journal:  Clin Exp Dermatol       Date:  2009-05-05       Impact factor: 3.470

2.  IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid.

Authors:  Lenche Chakievska; Maike M Holtsche; Axel Künstner; Stephanie Goletz; Britt-Sabina Petersen; Diamant Thaci; Saleh M Ibrahim; Ralf J Ludwig; Andre Franke; Christian D Sadik; Detlef Zillikens; Christoph Hölscher; Hauke Busch; Enno Schmidt
Journal:  J Autoimmun       Date:  2018-09-13       Impact factor: 7.094

3.  Secukinumab decreased circulating anti-BP180-NC16a autoantibodies in a patient with coexisting psoriasis vulgaris and bullous pemphigoid.

Authors:  Masahiro Kamata; Yoshihide Asano; Rino Shida; Narumi Maeda; Ayumi Yoshizaki; Tomomitsu Miyagaki; Tomohiko Kawashima; Yayoi Tada; Shinichi Sato
Journal:  J Dermatol       Date:  2019-01-10       Impact factor: 4.005

4.  Psoriasis and basement-membrane laminin.

Authors:  J P McFadden; A Powles; I Kimber; L Fry
Journal:  Br J Dermatol       Date:  2013-09       Impact factor: 9.302

5.  Coexistence of autoimmune bullous diseases (AIBDs) and psoriasis: A series of 145 cases.

Authors:  Chika Ohata; Norito Ishii; Hiroshi Koga; Shunpei Fukuda; Chiharu Tateishi; Daisuke Tsuruta; Minao Furumura; Takashi Hashimoto
Journal:  J Am Acad Dermatol       Date:  2015-04-18       Impact factor: 11.527

6.  Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab.

Authors:  Chihiro Nakayama; Yasuyuki Fujita; Mika Watanabe; Hiroshi Shimizu
Journal:  J Dermatol       Date:  2015-05-25       Impact factor: 4.005

7.  Successful secukinumab treatment of active bullous pemphigoid and chronic severe psoriasis: a case report.

Authors:  Jenny Sw Yun; Laura Scardamaglia; Chin-Guan Tan; Christopher J McCormack
Journal:  Australas J Dermatol       Date:  2022-02-09       Impact factor: 2.875

Review 8.  Guselkumab-associated bullous pemphigoid in a psoriasis patient: A case report and review of the literature.

Authors:  Martina Burlando; Niccolò Capurro; Astrid Herzum; Emanuele Cozzani; Aurora Parodi
Journal:  Dermatol Ther       Date:  2021-11-30       Impact factor: 3.858

9.  The Global, Regional, and National Burden of Psoriasis: Results and Insights From the Global Burden of Disease 2019 Study.

Authors:  Giovanni Damiani; Nicola Luigi Bragazzi; Chante Karimkhani Aksut; Dongze Wu; Gianfranco Alicandro; Dennis McGonagle; Cui Guo; Robert Dellavalle; Ayman Grada; Priscilla Wong; Carlo La Vecchia; Lai-Shan Tam; Kevin D Cooper; Mohsen Naghavi
Journal:  Front Med (Lausanne)       Date:  2021-12-16

Review 10.  Bullous Pemphigoid: Trigger and Predisposing Factors.

Authors:  Francesco Moro; Luca Fania; Jo Linda Maria Sinagra; Adele Salemme; Giovanni Di Zenzo
Journal:  Biomolecules       Date:  2020-10-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.